Amgen Showcases Groundbreaking Research at EULAR 2026 on Rare Autoimmune Disorders
Amgen Showcases Groundbreaking Research at EULAR 2026 on Rare Autoimmune Disorders
Amgen Inc. (NASDAQ: AMGN) is set to present pivotal new data regarding rare autoimmune and inflammatory diseases at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, held in London from June 3 to June 6. The latest findings from the Phase 3 MITIGATE trial of UPLIZNA (inebilizumab) will be highlighted, alongside new real-world evidence supporting TAVNEOS (avacopan).
Key Data Presentation
The MITIGATE trial has shed light on the biology of immunoglobulin G4-related disease (IgG4-RD). This chronic and severe condition necessitates effective long-term treatments, as current therapeutic options are often limited. The findings affirm UPLIZNA’s long-term safety profile and its commitment to enhancing the management of IgG4-RD.
Dr. Paul Burton, Amgen's Chief Medical Officer, noted, “Despite advances, patients with rare autoimmune diseases face considerable unmet medical needs. The data at EULAR bolster our understanding of these conditions by showcasing the capabilities of our pharmaceutical portfolio.”
Insights into UPLIZNA
The new data reveal that UPLIZNA treatment in the Open-Label Period (OLP) demonstrated sustained results. Notably:
- - Flare Incidence: An impressive 71.4% of patients receiving UPLIZNA achieved flare-free and glucocorticoid-free remission at the one-year mark, with zero flare occurrences among patients who continued the treatment.
- - Safety Profile: The adverse event rates remained consistent with previously established data, predominantly featuring mild respiratory infections. These findings reflect a reassuring outlook on UPLIZNA's efficacy and long-term use.
Additionally, a landmark natural history analysis of IgG4-RD will underline the unpredictable patterns of the disease, offering insights into potential early biomarkers for timely intervention and comprehensive monitoring strategies.
TAVNEOS and Real-World Evidence
Amgen is equally excited to share new evidence about TAVNEOS, which is making strides in managing anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis. In a large cohort study of 159 patients, real-world results demonstrated a significant reduction in glucocorticoid reliance, a vital point given the adverse long-term effects of corticosteroids.
Dr. Naomi Patel, a rheumatologist involved in the study, stated, “The outcomes illustrate that many patients achieve meaningful control over their disease, minimizing the heavy reliance on glucocorticoids.” This could represent an important shift in treating ANCA-associated vasculitis, as efforts to reduce glucocorticoid therapy could considerably lessen the treatment burden.
Conclusion
Amgen's presentations at EULAR 2026 signify a major leap forward in understanding and treating rare autoimmune diseases. With both UPLIZNA and TAVNEOS showing promising results, Amgen reaffirms its commitment to advancing therapeutics that address complex autoimmune disorders. As the congress unfolds, additional presentations will further elucidate these findings, paving the way for better patient outcomes in previously challenging chronic diseases.
For further information on abstracts and presentation schedules, visit Amgen's official communication platform.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.